[Embryonic stem cells - a scientific by-product of the assisted reproduction technology?].
The differentiation potential of embryonic stem (ES) cells seems to be higher when compared to adult stem cells, which mainly differentiate into certain tissue types only. ES cells have the potential to play an important role in regenerative medicine as demonstrated with murine ES cells. However, with human embryonic stem cells (hESC) several obstacles still have to be overcome, when these are to be used in clinical applications. The expansion of hESC, safety issues as well as the immune-tolerance after transplantation are all problems that still have to be solved. Since 2005 the derivation of hESC lines from super-numerous embryos has become permitted in Switzerland, albeit under strictly restrictive guidelines. In 2008 the Basler hESC laboratory was successful in derivating the first hESC line with a normal chromosome complement in Switzerland (CHES2). Now, new applications allow the personalized establishment of immune-tolerant stem cells, which lead to the replacement of therapeutic cloning by induced pluripotent stem cells (iPS).
Sterthaus
Oliver
O
Frauenspital, Universität Basel, Schweiz. osterthaus@uhbs.ch
Zhang
Hong
H
De Geyter
Christian
C
D000818:Animals; D002460:Cell Line; D019976:Cloning, Organism / Q000331:legislation & jurisprudence; D033041:Embryo Research / Q000331:legislation & jurisprudence; D053595:Embryonic Stem Cells / Q000276:immunology / Q000637:transplantation*; D019983:Guideline Adherence / Q000331:legislation & jurisprudence; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D039904:Pluripotent Stem Cells / Q000276:immunology / Q000637:transplantation; D027724:Reproductive Techniques, Assisted; D017634:Self Tolerance / Q000276:immunology; D013557:Switzerland